N

    Nuwellis Inc (NUWE)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.79
    -0.10 (-10.84%)

    Market Cap: $2.82M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    82%(32/39)
    Avg Surprise
    -8.06%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.39
    Range$-0.39 - $-0.39
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.35+10.3%
    60d ago$-0.33+15.4%
    30d ago$-0.33+15.4%
    7d ago$-0.33+15.4%
    Current$-0.39
    Revenue Consensus
    $3M
    Range$3M - $3M
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.22
    Range$-0.22 - $-0.22
    1 analysts
    Revenue Consensus
    $13M
    Range$13M - $13M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.22---
    Sep 26EST
    		-$-0.39---
    Jun 26
    		$-26.64$-23.80-11.93%Miss+98.8%
    Mar 26
    		$-73.15$-35.00-109.00%Miss+92.8%
    Dec 25
    		$-1.50$-1.56+3.85%Beat-240.9%
    Sep 25
    		$19.60N/A+103.25%Beat-99.2%
    Jun 25
    		$-2134.65$-661.50-222.70%Miss+92.3%
    Mar 25
    		$-1014.30$-661.50-53.33%Miss-168950.0%
    Dec 24
    		$-0.44$-0.43-2.33%Miss+100.0%
    Sep 24
    		$2557.81$-1881.60+235.94%Beat+102.7%
    Jun 24
    		$-27709.56$-12120.18-128.62%Beat+85.2%
    Mar 24
    		$-0.60$-1.06+43.40%Beat+100.0%
    Dec 23
    		$-115248.35$-71515.71-61.15%Beat-2304867.0%
    Sep 23
    		$-93124.78$-160181.48+41.86%Beat+90.7%
    Jun 23
    		$-187793.06$-207001.12+9.28%Beat+81.2%
    Mar 23
    		$-261820.06$-430123.29+39.13%Beat+73.8%
    Dec 22
    		$-5.00N/A+70.74%Beat+87.8%
    Sep 22
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 22
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 22
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 21
    		$-41.00$-47.67+13.99%Beat+73.9%
    Sep 21
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 21
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 21
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 20
    		$-157.00$-191.00+17.80%Beat+95.3%
    Sep 20
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 20
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 20
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 19
    		$-3360.00$-2400.00-40.00%Miss+86.6%
    Sep 19
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 19
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 19
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 18
    		$-25110.00$-22680.00-10.71%Miss+86.6%
    Sep 18
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 18
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Mar 18
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Dec 17
    		$-187320.00$-52920.00-253.97%Beat-380.6%
    Sep 17
    		$-1000000.00$-1000000.00+0.00%Beat+0.0%
    Jun 17
    		$-1000000.00$-1000000.00+0.00%Beat-
    Mar 17
    		$-1000000.00$-1000000.00+0.00%Beat-
    Dec 16
    		$-38976.00N/AN/ABeat-
    Sep 16
    		$-1000000.00$-1000000.00+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.01EV/EBITDA-0.34x
    Price/FCF-0.01xFCF Yield-8781.28%
    Profitability
    Profit Margin-125.60%Operating Margin-160.90%
    ROE-609.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.97xQuick Ratio1.54x
    Trading Statistics
    Beta0.29Avg Volume3.46M
    52-Week High$183.0552-Week Low$0.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.03
    SMA 20$1.26
    SMA 50$2.26
    SMA 200$43.06
    EMA 10$1.04
    EMA 20$1.39
    EMA 50$5.14
    EMA 200$113.24

    MACD

    Line: -0.68Signal: -0.82Hist: 0.15

    ADX

    ADX: 17.5+DI: 12.2-DI: 12.6

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down100.0
    PSAR$1.59

    Bollinger Bands

    Upper Band$1.83
    Lower Band$0.69
    %B Position9051%(Upper)
    Band Width0.09

    RSI (14-Day)

    Oversold
    29.2

    Momentum Oscillators

    Stoch %K5.7
    Stoch %D7.0
    Williams %R-95.0
    ROC (10d)-37.1%
    Momentum-0.47
    CCI (20d)-135.4
    MFI (14d)77.6

    Volatility Measures

    ATR (14d)$0.75(94.2%)
    StdDev (20d)0.29
    Hist Vol107.1%(High)

    Volume Flow

    VWAP$0.81
    OBV631.8M
    AD Line5747.2B
    CMF (20d)-0.575

    Volume Metrics

    Avg Vol (20d)3.6M
    Vol Ratio0.2x(Low)
    VWMA (20d)$1.48

    Pivot Points

    R3$1.19
    R2$1.12
    R1$1.00
    Pivot Point$0.93
    S1$0.82
    S2$0.75
    S3$0.63

    Advanced Oscillators

    TSI-36.23
    Ultimate Osc25.1
    KST-526.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.97M$2.40M$2.42M$2.22M$1.73M$1.90M$2.32M$2.37M$2.19M$1.86M$2.55M$2.41M
    Cost of Revenue$471,000$719,000$770,000$772,000$767,000$837,000$967,000$711,000$720,000$666,000$1.16M$1.03M
    Gross Profit$1.50M$1.68M$1.65M$1.45M$958,000$1.07M$1.35M$1.66M$1.47M$1.19M$1.39M$1.38M
    Operating Expenses$4.67M$6.25M$4.10M$4.14M$3.86M$4.13M$3.74M$3.19M$3.79M$5.94M$4.98M$4.54M
    R&D$942,000$1.73M$884,000$603,000$675,000$550,000$831,000$486,000$558,000$1.33M$1.37M$1.12M
    SG&A$3.73M$4.52M$3.21M$3.54M$3.19M$3.58M$2.91M$2.70M$3.24M$4.61M$3.61M$3.43M
    Operating Income$-3,169,000$-4,568,000$-2,443,000$-2,697,000$-2,906,000$-3,060,000$-2,387,000$-1,532,000$-2,320,000$-4,749,000$-3,593,000$-3,164,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$1.66M$0$0$0$9.64M$0$0$0$5.40M$0$1.91M$204,000
    Income Before Tax$-4,828,000$-4,541,000$-2,422,000$468,000$-12,549,000$-3,013,000$-1,467,000$2.36M$-7,723,000$-4,328,000$-5,507,000$-3,368,000
    Income Tax Expense$0$0$-1,000$0$4,000$1,000$1,000$0$2,000$2,000$2,000$2,000
    Net Income$-4,828,000$-4,541,000$-2,422,000$468,000$-12,553,000$-3,014,000$-1,468,000$2.36M$-7,725,000$-4,330,000$-5,509,000$-3,370,000
    EBITDA$-4,791,000$-4,503,000$-2,061,000$511,000$-12,499,000$-2,940,000$-1,378,000$2.43M$-7,648,000$-4,252,000$-1,915,000$-3,284,000
    EBIT$-4,828,000$-4,541,000$-2,422,000$468,000$-12,549,000$-3,013,000$-1,461,000$2.36M$-7,723,000$-4,328,000$-5,507,000$-3,368,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NUWE

    Government Contracts

    Gov Obligations (TTM)
    $20000
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24225P1357Department of Veterans AffairsDepartment of Veterans Affairs$20000Aug 21, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical

    Nuwellis, Inc. and Atrility Medical, Inc. have announced a co-promotion and distribution agreement for Atrility's AtriAmp® device, expanding Nuwellis' pediatric and critical care portfolio. The agreement includes an initial six-month co-promotion phase, with Nuwellis potentially becoming the exclusive U.S. distributor. The AtriAmp device, which is FDA-cleared for adult and pediatric patients, provides continuous real-time atrial electrograms for patients with temporary epicardial pacing wires, complementing Nuwellis' focus on critical care medicine.

    The Manila Times•8/25/26•
    Bullish

    After a six-month pilot, Nuwellis may distribute a heart device across much of the U.S.

    Nuwellis (Nasdaq: NUWE) has entered a staged co-promotion and distribution agreement with Atrility Medical for its FDA-cleared AtriAmp device. This initial six-month pilot covers three Nuwellis sales territories, with the potential for Nuwellis to become Atrility’s exclusive U.S. distributor for much of the country upon successful completion of the pilot. The agreement expands Nuwellis’ pediatric and critical care portfolio and leverages its existing commercial infrastructure for capital-efficient growth.

    Stock Titan•8/25/26•
    Somewhat-Bearish

    Nuwellis study shows epoprostenol safe for pediatric Aquadex therapy

    Nuwellis announced that a study published in Frontiers in Pediatrics confirms epoprostenol is a safe and feasible anticoagulant for pediatric Aquadex ultrafiltration therapy. The retrospective review of 46 children at UPMC Children’s Hospital showed no bleeding complications and stable platelet counts over 52 treatment courses. This finding is crucial for critically ill pediatric patients who cannot tolerate conventional anticoagulants, expanding the Aquadex system's use in pediatric intensive care.

    scanx.trade•8/24/26•
    Bullish

    Nuwellis Posts 14% Revenue Jump in Q2 2026, Misses on EPS

    Nuwellis, Inc. (NASDAQ:NUWE) reported mixed Q2 2026 results, with revenue growing 14% year-over-year to $2.0M, meeting expectations. However, the company significantly missed on EPS with a loss of $26.64 per share and a net loss of $4.8M. Investors reacted negatively, causing NUWE shares to drop 3.5%.

    AlphaStreet•8/14/26•
    Somewhat-Bearish

    Armistice Capital (NUWE) trims Nuwellis ownership to a 4.99% disclosed stake

    Armistice Capital, LLC and Steven Boyd have reported an amended ownership stake in Nuwellis, Inc. (NUWE), now holding 73,367 shares, which represents 4.99% of the outstanding common stock. This filing indicates that all voting and dispositive power over these shares is shared between Armistice Capital and Steven Boyd, with the shares directly held by Armistice Capital Master Fund Ltd. The reduction to just under 5% means they are no longer required to file certain beneficial ownership reports.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About NUWE

    Does NUWE pay dividends?
    Nuwellis Inc (NUWE) does not currently pay a regular dividend.
    What is NUWE's market cap?
    Nuwellis Inc (NUWE) has a market capitalization of $2.82M with a current stock price of $0.79.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In